Skip Navigation


European Heart Journal Advance Access originally published online on September 5, 2006
European Heart Journal 2006 27(19):2370; doi:10.1093/eurheartj/ehl241
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/19/2370    most recent
ehl241v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jolobe, O. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jolobe, O. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Stroke prophylaxis in atrial fibrillation

Oscar M. Jolobe

Manchester Medical Society
Medical Division
The Lodge
842 Wilmslow Road
Didsbury
Manchester
Lancashire M20 2RN
UK
Tel: +44 1614489034
E-mail address: oscarjolobe@yahoo.co.uk

The first 10% of the full text of this article appears below.

The fact that patients aged >80 had clearly reduced chances of getting the recommended warfarin treatment even in the absence of contraindications1 is a reflection of the distrust that some clinicians have of the validity . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?